Bajaj Healthcare Reports Strong Q2 FY27 Earnings Driven by Formulations Growth
Bajaj Healthcare Ltd 路 Press Release 路 18 Oct 2026, 3:58 am
Bajaj Healthcare Reports Strong Q2 FY27 Earnings Driven by Formulations Growth Bajaj Healthcare posted an 18.9% YoY increase in Q2 FY27 revenue from operations to Rs. 175.9 Crore, with EBITDA rising 12.2% YoY to Rs. 32.1 Crore and PAT growing 26.9% YoY to Rs. 14.1 Crore. Formulations surged 82.0% YoY to Rs. 41.7 Crore, while API exports expanded 28.5% YoY to Rs. 62.6 Crore. The company secured first-in-India DCGI approval and commenced commercial rollout for Cenobamate Tablets in Sep'26. Additionally, India Ratings upgraded its long-term rating to IND A/Stable.
Original exchange filing (PDF)
More announcements from Bajaj Healthcare Ltd
- Intimation for allotment of 26,710 Equity Shares pursuant to exercise of ESOPs 路 18 Nov 2026
- Transcript of Earnings Call for Q2H1FY27 路 27 Oct 2026
- Intimation for Audio Recording of Earnings Call for Q2FY27 路 20 Oct 2026
- Statement of Deviation & Variation for the quarter ended September 30, 2026 路 17 Oct 2026
- Monitoring Agency Report for the quarter ended September 30, 2026 路 17 Oct 2026
- Financial Results for the quarter ended September 30, 2026 路 17 Oct 2026
- Bajaj Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 17 Oct 2026
- Outcome of the Board Meeting held on 17th October 2026 路 17 Oct 2026
